- Home
- PBYI vs MDWD Comparison
PBYI vs MDWD Comparison
Compare PBYI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- MDWD
- Stock Information
- Founded
- PBYI 2010
- MDWD 2000
- Country
- PBYI United States
- MDWD Israel
- Employees
- PBYI N/A
- MDWD N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- PBYI Health Care
- MDWD Health Care
- Exchange
- PBYI Nasdaq
- MDWD Nasdaq
- Market Cap
- PBYI 153.2M
- MDWD 184.8M
- IPO Year
- PBYI N/A
- MDWD 2014
- Fundamental
- Price
- PBYI $3.09
- MDWD $19.02
- Analyst Decision
- PBYI Strong Buy
- MDWD Strong Buy
- Analyst Count
- PBYI 1
- MDWD 1
- Target Price
- PBYI $7.00
- MDWD $25.00
- AVG Volume (30 Days)
- PBYI 754.5K
- MDWD 61.7K
- Earning Date
- PBYI 02-27-2025
- MDWD 11-26-2024
- Dividend Yield
- PBYI N/A
- MDWD N/A
- EPS Growth
- PBYI 492.79
- MDWD N/A
- EPS
- PBYI 0.47
- MDWD N/A
- Revenue
- PBYI $243,569,000.00
- MDWD $19,720,000.00
- Revenue This Year
- PBYI N/A
- MDWD $10.37
- Revenue Next Year
- PBYI N/A
- MDWD $26.36
- P/E Ratio
- PBYI $6.63
- MDWD N/A
- Revenue Growth
- PBYI 6.30
- MDWD N/A
- 52 Week Low
- PBYI $2.23
- MDWD $11.04
- 52 Week High
- PBYI $7.73
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- PBYI 49.17
- MDWD 61.79
- Support Level
- PBYI $2.92
- MDWD $15.80
- Resistance Level
- PBYI $4.06
- MDWD $18.25
- Average True Range (ATR)
- PBYI 0.29
- MDWD 0.88
- MACD
- PBYI 0.01
- MDWD 0.07
- Stochastic Oscillator
- PBYI 27.07
- MDWD 95.27
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.